This article is more than 5 years old. Information may no longer be current.

Ocriplasmin approved for treatment of symptomatic vitreomacular adhesion

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Food and Drug Administration has approved ocriplasmin to treat symptomatic vitreomacular adhesion, according to a news release from ThromboGenics.

The approval follows a phase 3 program in which Jetrea (ocriplasmin) was superior to placebo for the treatment of symptomatic vitreomacular adhesion. In two trials, 26.5% of patients who received ocriplasmin had resolution of vitreomacular adhesion compared with 10.1% of patients who received placebo (P < .01). Most adverse events with ocriplasmin were mild and transient, according to the release.

The recommended dose of ocriplasmin is 0.125 mg (0.1 mL) of the diluted solution delivered to the affected eye by intravitreal injection.

The agent is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three important parts of the vitreoretinal interface that are involved with vitreomacular adhesion, the release said.

ThromboGenics intends to launch Jetrea in the United States in January, CEO Patrik De Haes, MD, said in the release.